A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus

Inclusion Criteria: * 1.1nformed Consent signed by the subject * 1.2 Male and female subjects 18 - 60 years of age (inclusive) * 1.3 Skin colour Type I, II, or III according to Fitzpatrick Scale (see Appendix 1) * 1.4 Type 1 diabetes diagnosed \> 12 months ago * 1.5 Intensified insulin therapy scheme using multiple daily injection (MDI) or continuous subcutaneous insulin infusion (CSII) for more than 6 months * 1.6 BMI between 18.5 and 28.0 kg/m2 * 1.7 Using a CGM/FGM system (Freestyle Libre2, Freestyle Libre3, Dexcom G6 or Dexcom G7) * 1.8 Willingness to follow the study procedure Exclusion Criteria: * 2.1 In female subjects: pregnancy or breastfeeding period (self-reported) * 2.2 HbA1c of \> 9.0% (based on last measurement by treating physician but not older than 120 days) Note: To be repeated at the study site if measurement is older than 120 days or not available * 2.3 History of cardiovascular diseases * 2.4 Irregular 12-lead ECG upon investigator's judgement * 2.5 Medical history of epilepsy or other neurological disease associated with seizure events * 2.6 Atypical skin condition (e.g., Hyperkeratosis, Hyperpigmentation) or presence of tattoos or scars in the measurement area (wrist) that could impair validity of measurement upon investigator's judgement * 2.7 Known sensitivity to medical grade adhesives or other skin-related complications, which might influence the outcome * 2.8 Not able to understand, write or read German * 2.9 Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation * 2.10 Enrolment of the PI, his/her family members, employees and other dependent persons